BioSyent Inc. MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include:  (CAD) Q1 2024 % Change vs.Q1 2023 Trailing Twelve Months(TTM) March 31, 2024 % Change vs.TTMMarch 31, 2023 Canadian Pharma Sales 7,546,144